WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics
2009
Introduction
5-HT2C agonists, by decreasing mesolimbic dopamine without affecting nigrostriatal dopamine, are predicted to have antipsychotic efficacy with low extrapyramidal side effects (EPS). Combining 5-HT2C agonists with low doses of existing antipsychotics could increase treatment efficacy while reducing treatment liabilities such as EPS (typical antipsychotics), and the propensity for weight gain (atypical antipsychotics).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
43
References
22
Citations
NaN
KQI